journal
MENU ▼
Read by QxMD icon Read
search

EJNMMI Research

journal
https://www.readbyqxmd.com/read/29667074/on-the-optimal-z-score-threshold-for-siscom-analysis-to-localize-the-ictal-onset-zone
#1
Liesbeth De Coster, Koen Van Laere, Evy Cleeren, Kristof Baete, Patrick Dupont, Wim Van Paesschen, Karolien E Goffin
BACKGROUND: In epilepsy patients, SISCOM or subtraction ictal single photon emission computed tomography co-registered to magnetic resonance imaging has become a routinely used, non-invasive technique to localize the ictal onset zone (IOZ). Thresholding of clusters with a predefined number of standard deviations from normality (z-score) is generally accepted to localize the IOZ. In this study, we aimed to assess the robustness of this parameter in a group of patients with well-characterized drug-resistant epilepsy in whom the exact location of the IOZ was known after successful epilepsy surgery...
April 17, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29663167/structural-studies-on-radiopharmaceutical-dota-minigastrin-analogue-cp04-complexes-and-their-interaction-with-cck2-receptor
#2
Piotr F J Lipiński, Piotr Garnuszek, Michał Maurin, Raphael Stoll, Nils Metzler-Nolte, Artur Wodyński, Jan Cz Dobrowolski, Marta K Dudek, Monika Orzełowska, Renata Mikołajczak
BACKGROUND: The cholecystokinin receptor subtype 2 (CCK-2R) is an important target for diagnostic imaging and targeted radionuclide therapy (TRNT) due to its overexpression in certain cancers (e.g., medullary thyroid carcinoma (MTC)), thus matching with a theranostic principle. Several peptide conjugates suitable for the TRNT of MTC have been synthesized, including a very promising minigastrin analogue DOTA-(DGlu)6 -Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 (CP04). In this contribution, we wanted to see whether CP04 binding affinity for CCK-2R is sensitive to the type of the complexed radiometal, as well as to get insights into the structure of CP04-CCK2R complex by molecular modeling...
April 16, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29651571/correlation-of-neuropsychological-and-metabolic-changes-after-epilepsy-surgery-in-patients-with-left-mesial-temporal-lobe-epilepsy-with-hippocampal-sclerosis
#3
Canan Güvenç, Patrick Dupont, Jan Van den Stock, Laura Seynaeve, Kathleen Porke, Eva Dries, Karen Van Bouwel, Johannes van Loon, Tom Theys, Karolien E Goffin, Wim Van Paesschen
BACKGROUND: Epilepsy surgery often causes changes in cognition and cerebral glucose metabolism. Our aim was to explore relationships between pre- and postoperative cerebral metabolism as measured with 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) and neuropsychological test scores in patients with left mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS), who were rendered seizure-free after epilepsy surgery. RESULTS: Thirteen patients were included...
April 12, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29651569/external-radiation-exposure-excretion-and-effective-half-life-in-177-lu-psma-targeted-therapies
#4
J Kurth, B J Krause, S M Schwarzenböck, L Stegger, M Schäfers, K Rahbar
BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted therapy with 177 Lu-PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC). To optimize the therapy procedure, it is necessary to determine relevant parameters to define radiation protection and safety necessities. Therefore, this study aimed at estimating the ambient radiation exposure received by the patient. Moreover, the excreted activity was quantified. RESULTS: In total, 50 patients with mCRPC and treated with 177 Lu-PSMA-617 (mean administered activity 6...
April 12, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29651565/synthesis-and-preclinical-evaluation-of-novel-18-f-labeled-glu-urea-glu-based-psma-inhibitors-for-prostate-cancer-imaging-a-comparison-with-18-f-dcfpyl-and-18-f-psma-1007
#5
Stephanie Robu, Alexander Schmidt, Matthias Eiber, Margret Schottelius, Thomas Günther, Behrooz Hooshyar Yousefi, Markus Schwaiger, Hans-Jürgen Wester
BACKGROUND: Due to its high and consistent expression in prostate cancer (PCa), the prostate-specific membrane antigen (PSMA) represents an ideal target for molecular imaging and targeted therapy using highly specific radiolabeled PSMA ligands. To address the continuously growing clinical demand for 18 F-labeled PSMA-probes, we developed two novel Glu-urea-Glu-(EuE)-based inhibitors, EuE-k-18 F-FBOA (1) and EuE-k-β-a-18 F-FPyl (2), both with optimized linker structure and different 18 F-labeled aromatic moieties...
April 12, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29644499/evaluation-of-prognostic-models-developed-using-standardised-image-features-from-different-pet-automated-segmentation-methods
#6
Craig Parkinson, Kieran Foley, Philip Whybra, Robert Hills, Ashley Roberts, Chris Marshall, John Staffurth, Emiliano Spezi
BACKGROUND: Prognosis in oesophageal cancer (OC) is poor. The 5-year overall survival (OS) rate is approximately 15%. Personalised medicine is hoped to increase the 5- and 10-year OS rates. Quantitative analysis of PET is gaining substantial interest in prognostic research but requires the accurate definition of the metabolic tumour volume. This study compares prognostic models developed in the same patient cohort using individual PET segmentation algorithms and assesses the impact on patient risk stratification...
April 11, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29633046/assessment-of-glucose-metabolism-and-cellular-proliferation-in-multiple-myeloma-a-first-report-on-combined-18-f-fdg-and-18-f-flt-pet-ct-imaging
#7
C Sachpekidis, H Goldschmidt, K Kopka, A Kopp-Schneider, A Dimitrakopoulou-Strauss
BACKGROUND: Despite the significant upgrading in recent years of the role of 18 F-FDG PET/CT in multiple myeloma (MM) diagnostics, there is a still unmet need for myeloma-specific radiotracers. 3'-Deoxy-3'-[18 F]fluorothymidine (18 F-FLT) is the most studied cellular proliferation PET agent, considered a potentially new myeloma functional imaging tracer. The aim of this pilot study was to evaluate 18 F-FLT PET/CT in imaging of MM patients, in the context of its combined use with 18 F-FDG PET/CT...
April 10, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29619657/hallmarks-in-prostate-cancer-imaging-with-ga68-psma-11-pet-ct-with-reference-to-detection-limits-and-quantitative-properties
#8
Alejandro Sanchez-Crespo, Emma Jussing, Ann-Charlotte Björklund, Katja Pokrovskaja Tamm
BACKGROUND: Gallium-68-labeled prostate-specific antigen positron emission tomography/computed tomography imaging (Ga68-PSMA-11-PET/CT) has emerged as a potential gold standard for prostate cancer (PCa) diagnosis. However, the imaging limitations of this technique at the early state of PCa recurrence/metastatic spread are still not well characterized. The aim of this study was to determine the quantitative properties and the fundamental imaging limits of Ga68-PSMA-11-PET/CT in localizing small PCa cell deposits...
April 4, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29619584/using-in-vivo-fluorescence-lifetime-imaging-to-detect-her2-positive-tumors
#9
Yasaman Ardeshirpour, Dan L Sackett, Jay R Knutson, Amir H Gandjbakhche
BACKGROUND: Assessment of the status of tumor biomarkers in individual patients would facilitate personalizing treatment strategy, and continuous monitoring of those biomarkers and their binding process to the therapeutic drugs would provide a means for early evaluation of the efficacy of therapeutic intervention. Fluorescent probes can accumulate inside the tumor region due to the leakiness of its vascularization and this can make it difficult to distinguish if the measured fluorescence intensity is from probes bound to target receptors or just accumulated unbound probes inside the tumor...
April 4, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29616369/treatment-response-assessment-with-r-11-cpaq-pet-in-the-mmtv-pymt-mouse-model-of-breast-cancer
#10
T Tegnebratt, L Lu, S Eksborg, A Chireh, P Damberg, S Nikkhou-Aski, T Foukakis, H Rundqvist, S Holmin, R V Kuiper, E Samen
BACKGROUND: The goal of the study was to assess the potential of the vascular endothelial growth factor receptor (VEGFR)-2-targeting carbon-11 labeled (R)-N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-3-piperidinyl)methoxy)-4-quinazolineamine ((R)-[11 C]PAQ) as a positron emission tomography (PET) imaging biomarker for evaluation of the efficacy of anticancer drugs in preclinical models. METHODS: MMTV-PyMT mice were treated with vehicle alone (VEH), murine anti-VEGFA antibody (B20-4...
April 3, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29594931/validation-of-18-f-flt-as-a-perfusion-independent-imaging-biomarker-of-tumour-response-in-egfr-mutated-nsclc-patients-undergoing-treatment-with-an-egfr-tyrosine-kinase-inhibitor
#11
R Iqbal, G M Kramer, V Frings, E F Smit, O S Hoekstra, R Boellaard
BACKGROUND: 3'-Deoxy-3'-[18 F]fluorothymidine ([18 F]FLT) was proposed as an imaging biomarker for the assessment of in vivo cellular proliferation with positron emission tomography (PET). The current study aimed to validate [18 F]FLT as a perfusion-independent PET tracer, by gaining insight in the intra-tumoural relationship between [18 F]FLT uptake and perfusion in non-small cell lung cancer (NSCLC) patients undergoing treatment with a tyrosine kinase inhibitor (TKI). Six patients with metastatic NSCLC, having an activating epidermal growth factor receptor (EGFR) mutation, were included in this study...
March 27, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29589224/comparison-of-three-parameter-kinetic-model-analysis-to-standard-patlak-s-analysis-in-18-f-fdg-pet-imaging-of-lung-cancer-patients
#12
E Laffon, M L Calcagni, G Galli, A Giordano, A Capotosti, R Marthan, L Indovina
BACKGROUND: Patlak's graphical analysis can provide tracer net influx constant (Ki) with limitation of assuming irreversible tracer trapping, that is, release rate constant (kb ) set to zero. We compared linear Patlak's analysis to non-linear three-compartment three-parameter kinetic model analysis (3P-KMA) providing Ki, kb , and fraction of free18 F-FDG in blood and interstitial volume (Vb ). METHODS: Dynamic PET data of 21 lung cancer patients were retrospectively analyzed, yielding for each patient an18 F-FDG input function (IF) and a tissue time-activity curve...
March 27, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29589155/accuracy-of-tumor-segmentation-from-multi-parametric-prostate-mri-and-18-f-choline-pet-ct-for-focal-prostate-cancer-therapy-applications
#13
Morand Piert, Prasad R Shankar, Jeffrey Montgomery, Lakshmi Priya Kunju, Virginia Rogers, Javed Siddiqui, Thekkelnaycke Rajendiran, Jason Hearn, Arvin George, Xia Shao, Matthew S Davenport
BACKGROUND: The study aims to assess the accuracy of multi-parametric prostate MRI (mpMRI) and18 F-choline PET/CT in tumor segmentation for clinically significant prostate cancer.18 F-choline PET/CT and 3 T mpMRI were performed in 10 prospective subjects prior to prostatectomy. All subjects had a single biopsy-confirmed focus of Gleason ≥ 3+4 cancer. Two radiologists (readers 1 and 2) determined tumor boundaries based on in vivo mpMRI sequences, with clinical and pathologic data available...
March 27, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29523980/noninvasive-quantitation-of-rat-cerebral-blood-flow-using-99m-tc-hmpao-assessment-of-input-function-with-dynamic-chest-planar-imaging
#14
Chie Suzuki, Mutsumi Kosugi, Yasuhiro Magata
BACKGROUND: Cerebral blood flow (CBF) quantitation using technetium-99m hexamethylpropyleneamine oxime (99m Tc-HMPAO) generally requires assessment of input function by arterial blood sampling, which would be invasive for small animals. We therefore performed chest dynamic planar imaging, instead of arterial blood sampling, to estimate the input function and establish noninvasive quantitation method of rat CBF using the image-derived input function. RESULTS: Integrated radioactivity concentration in the heart-blood pool on planar images (AUCBlood -planar) was identical to that in arterial blood samples (AUCBlood -sampling)...
March 9, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29508107/i-124-codrituzumab-imaging-and-biodistribution-in-patients-with-hepatocellular-carcinoma
#15
Jorge A Carrasquillo, Joseph A O'Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Steven M Larson, Peter M Smith-Jones, Serge K Lyashchenko, Norihisa Ohishi, Toshihiko Ohtomo, Ghassan K Abou-Alfa
BACKGROUND: I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (~ 185 MBq, 10 mg). Seven of these patients undergoing sorafenib/immunotherapy with 2.5 or 5 mg/kg of cold codrituzumab had repeat imaging, with co-infusion of I-124 codrituzumab, as part of their immunotherapy treatment. Three patients who progressed while on sorafenib/immunotherapy were re-imaged after a 4-week washout period to assess for the presence of antigen...
March 5, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29500717/imaging-a%C3%AE-and-tau-in-early-stage-alzheimer-s-disease-with-18-f-av45-and-18-f-av1451
#16
Azadeh Firouzian, Alex Whittington, Graham E Searle, Ivan Koychev, Giovanna Zamboni, Simon Lovestone, Roger N Gunn
BACKGROUND: AD is a progressive neurodegenerative disorder that is associated with the accumulation of two different insoluble protein aggregates, Aβ plaques and hyperphosphorylated tau. This study aimed to investigate the optimal acquisition and quantification of [18 F]AV45 and [18 F]AV1451 to image Aβ and tau, respectively, in subjects with AD. Fifteen subjects with early stage AD underwent a T1-weighted structural MRI and two dynamic PET scans to image Aβ (60 min, [18 F]AV45) and tau (120 min, [18 F]AV1451)...
March 2, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29492782/biokinetic-and-dosimetric-aspects-of-64-cucl-2-in-human-prostate-cancer-possible-theranostic-implications
#17
Sergio Righi, Martina Ugolini, Gianluca Bottoni, Matteo Puntoni, Massimiliano Iacozzi, Francesco Paparo, Manlio Cabria, Luca Ceriani, Monica Gambaro, Luca Giovanella, Arnoldo Piccardo
BACKGROUND: The aim of the present study is to evaluate the kinetics and dosimetry of64 CuCl2 in human prostate cancer (PCa) lesions. We prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external beam radiation therapy. All patients underwent64 CuCl2 -PET/CT to detect PCa recurrence/metastases. Volumes of interest were manually drawn for each64 CuCl2 avid PCa lesion with a diameter > 1 cm on mpMRI in each patient. Time-activity curves for all lesions were obtained...
March 1, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29488080/hyperkalemia-in-patients-treated-with-endoradiotherapy-combined-with-amino-acid-infusion-is-associated-with-severe-metabolic-acidosis
#18
Christian H Pfob, Matthias Eiber, Peter Luppa, Florian Maurer, Tobias Maurer, Robert Tauber, Calogero D'Alessandria, Benedikt Feuerecker, Klemens Scheidhauer, Armin Ott, Uwe Heemann, Markus Schwaiger, Christoph Schmaderer
BACKGROUND: Amino acid co-infusion for renal protection in endoradiotherapy (ERT) applied as prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) or peptide receptor radionuclide therapy (PRRT) has been shown to cause severe hyperkalemia. The pathophysiology behind the rapid development of hyperkalemia is not well understood. We hypothesized that the hyperkalemia should be associated with metabolic acidosis. RESULTS: Twenty-two patients underwent ERT...
February 27, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29488030/labeling-of-dota-conjugated-hpma-based-polymers-with-trivalent-metallic-radionuclides-for-molecular-imaging
#19
Elisabeth Eppard, Ana de la Fuente, Nicole Mohr, Mareli Allmeroth, Rudolf Zentel, Matthias Miederer, Stefanie Pektor, Frank Rösch
BACKGROUND: In this work, the in vitro and in vivo stabilities and the pharmacology of HPMA-made homopolymers were studied by means of radiometal-labeled derivatives. Aiming to identify the fewer amount and the optimal DOTA-linker structure that provides quantitative labeling yields, diverse DOTA-linker systems were conjugated in different amounts to HPMA homopolymers to coordinate trivalent radiometals Me(III)* = gallium-68, scandium-44, and lutetium-177. RESULTS: Short linkers and as low as 1...
February 27, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29445878/feasibility-of-intraoperative-detection-of-sentinel-lymph-nodes-with-89-zirconium-labelled-nanocolloidal-albumin-pet-ct-and-a-handheld-high-energy-gamma-probe
#20
Derrek A Heuveling, K Hakki Karagozoglu, Arthur Van Lingen, Otto S Hoekstra, Guus A M S Van Dongen, Remco De Bree
BACKGROUND: PET/CT lymphoscintigraphy using 89 Zr-nanocolloidal albumin has the potential to improve the preoperative identification of sentinel lymph nodes (SLNs), especially if located in the near proximity of the primary tumour. This study aims to demonstrate the feasibility of PET/CT lymphoscintigraphy followed by intraoperative detection of 89 Zr-nanocolloidal albumin containing SLNs with the use of a handheld high-energy gamma probe. METHODS: PET/CT lymphoscintigraphy was performed after peritumoural injection of 89 Zr-nanocolloidal albumin in five patients with oral cavity carcinoma planned for surgical resection...
February 14, 2018: EJNMMI Research
journal
journal
43586
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"